Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Bioorganic & Medicinal Chemistry Letters - Tập 11 Số 14 - Trang 1911-1914 - 2001
Andrew Barker1, Keith H. Gibson2, Walter Grundy2, Andrew A. Godfrey2, Jeffrey J Barlow2, Mark P. Healy2, J.R. Woodburn2, Susan Ashton2, Brenda J Curry2, L. Scarlett2, Lianne Henthorn2, Laura M. Richards2
1AstraZeneca, Cancer and Infection Research, Mereside, Alderley Park, Macclesfield, SK10 4TG, Cheshire, UK.
2AstraZeneca, Cancer and Infection Research, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK

Tóm tắt

Từ khóa


Tài liệu tham khảo

Ward, 1994, Biochem. Pharmacol., 48, 659, 10.1016/0006-2952(94)90042-6

Wakeling, 1996, Breast Cancer Res. Treat., 38, 67, 10.1007/BF01803785

Wakeling, 1997, Endocr. Relat. Cancer, 4, 351, 10.1677/erc.0.0040351

Woodburn, 1999, Pharmacol. Ther., 82, 241, 10.1016/S0163-7258(98)00045-X

Rewcastle, 1995, J. Med. Chem., 38, 3482, 10.1021/jm00018a008

Denny, 1996, Clin. Exp. Pharmacol. Physiol., 23, 424, 10.1111/j.1440-1681.1996.tb02752.x

Gibson, 1997, Bioorg. Med. Chem. Lett., 7, 2723, 10.1016/S0960-894X(97)10059-2

Smaill, 1995, J. Med. Chem., 38, 1803

Fry, 2000, Anti-Cancer Drug Des., 15, 3

Woodburn, 1998, Cell. Mol. Biol. Lett., 3, 348

Thông tin
Thông tin xuất bản

Bioorganic & Medicinal Chemistry Letters

Tập 11 Số 14

1911-1914

Thông tin tác giả